Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shushe Weikexin is a Traditional Chinese Medicine (TCM) preparation developed by the Jilin Province Academy of Traditional Chinese Medicine for the treatment of peptic ulcer diseases, including duodenal and gastric ulcers. The formulation is designed to protect the gastric mucosa, inhibit excessive gastric acid secretion, and promote the healing of ulcerated tissues. It typically contains a combination of herbal extracts such as *Bletilla striata*, *Corydalis yanhusuo*, and *Glycyrrhiza uralensis*, which are known in TCM for their ability to 'invigorate the stomach,' relieve pain, and stop bleeding. Shushe Weikexin is primarily used in China and is often administered in oral forms like capsules or granules to manage symptoms of chronic gastritis and peptic ulcers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shushe Weikexin.